BeOne Medicines Files Interim Financial Report for H1 2026

Filing Overview

BeOne Medicines Ltd. (CIK: 0001651308) submitted a Form 8-K on August 26, 2026, to report on its recent financial disclosures.

Key Information

The primary purpose of this filing is to furnish information under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).

• Interim Report Filing: The company announced it has filed its 2026 Interim Report for the six months ended June 30, 2026, with the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. This report was prepared under the People's Republic of China's accounting standards (PRC GAAP).

• GAAP Reconciliation & R&D Data: Exhibit 99.1 was furnished to provide investors with key financial information prepared under U.S. GAAP. This includes:

  1. A summary of material differences between U.S. GAAP and PRC GAAP concerning share-based compensation, interim income taxes, leasing, and royalty transfers.
  2. A detailed breakdown of Research and Development (R&D) expenses by key products and projects for the six months ended June 30, 2026.

Financial Highlights (from Exhibit 99.1)

• Total R&D Expenses: The company reported total R&D expenses of $1.15 billion for the first half of 2026, an increase from $1.01 billion in the same period of 2025.
• Key Project Spending: Significant R&D investments were allocated to several key pipeline products, including:
  • BEQALZI (sonrotoclax): $74.0 million
  • Tacabrutideg (BTK-targeted CDAC): $44.3 million
  • BRUKINSA (zanubrutinib): $42.7 million
  • TEVIMBRA (tislelizumab): $37.1 million

Conclusion

This 8-K serves as a bridge for U.S. investors, providing crucial financial data aligned with U.S. GAAP following the company's mandatory reporting in China. The increase in R&D spending highlights the company's continued investment in its drug pipeline. The detailed breakdown of expenses offers valuable insight into the company's strategic priorities and the progress of its key clinical programs.